IT1164243B - Composizione farmaceutica contenente almeno in parte quantitativi terapeuticamente efficaci di endotossina detossificata raffinata ed il suo impiego terapeutico - Google Patents

Composizione farmaceutica contenente almeno in parte quantitativi terapeuticamente efficaci di endotossina detossificata raffinata ed il suo impiego terapeutico

Info

Publication number
IT1164243B
IT1164243B IT21288/83A IT2128883A IT1164243B IT 1164243 B IT1164243 B IT 1164243B IT 21288/83 A IT21288/83 A IT 21288/83A IT 2128883 A IT2128883 A IT 2128883A IT 1164243 B IT1164243 B IT 1164243B
Authority
IT
Italy
Prior art keywords
pharmaceutical composition
therapeutically effective
composition containing
therapeutic use
detoxified endotoxin
Prior art date
Application number
IT21288/83A
Other languages
English (en)
Other versions
IT8321288A0 (it
Inventor
Edgar Ernst Ribi
Steven Marc Schwartzman
John Leonard Cantrell
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of IT8321288A0 publication Critical patent/IT8321288A0/it
Application granted granted Critical
Publication of IT1164243B publication Critical patent/IT1164243B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IT21288/83A 1982-05-26 1983-05-25 Composizione farmaceutica contenente almeno in parte quantitativi terapeuticamente efficaci di endotossina detossificata raffinata ed il suo impiego terapeutico IT1164243B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/382,405 US4436728A (en) 1982-05-26 1982-05-26 Refined detoxified endotoxin product

Publications (2)

Publication Number Publication Date
IT8321288A0 IT8321288A0 (it) 1983-05-25
IT1164243B true IT1164243B (it) 1987-04-08

Family

ID=23508808

Family Applications (1)

Application Number Title Priority Date Filing Date
IT21288/83A IT1164243B (it) 1982-05-26 1983-05-25 Composizione farmaceutica contenente almeno in parte quantitativi terapeuticamente efficaci di endotossina detossificata raffinata ed il suo impiego terapeutico

Country Status (7)

Country Link
US (1) US4436728A (it)
JP (1) JPS58222025A (it)
CA (1) CA1217136A (it)
DE (1) DE3318567C2 (it)
FR (1) FR2527443B1 (it)
GB (1) GB2122083B (it)
IT (1) IT1164243B (it)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4505900A (en) * 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
NL8401226A (nl) * 1984-04-16 1985-11-18 Univ Utrecht Farmaceutisch produkt met anti-tumorwerking; gebruik van een farmaceutisch produkt of van farmaceutische samenstellingen in een anti-tumortherapie.
US4629722A (en) * 1984-07-12 1986-12-16 Ribi Immunochem Research, Inc. Method of inhibiting the onset of acute radiation syndrome
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US4845036A (en) * 1987-02-03 1989-07-04 The United States Of America As Represented By The Department Of Health And Human Services Process for isolation of the B oligomer of pertussis toxin
DE58903323D1 (de) * 1988-06-04 1993-03-04 Sartorius Gmbh Oberschalige elektronische waage.
US5416070A (en) * 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
US4950645A (en) * 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
AU704829B2 (en) * 1994-12-28 1999-05-06 University Of Kentucky Murine anti-idiotype antibody 3H1
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US20020041872A1 (en) * 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en) * 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US20020098190A1 (en) * 1997-06-13 2002-07-25 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US20020122807A1 (en) * 1998-07-07 2002-09-05 Dan Michael D. Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
US7534443B1 (en) 1998-07-16 2009-05-19 Ichiro Azuma Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
US20020068068A1 (en) * 1999-02-02 2002-06-06 Mahan Michael J. Method of creating antibodies and compositions used for same
AU4057300A (en) 1999-03-30 2000-10-16 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
AU2003213640A1 (en) * 2002-02-28 2003-09-16 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
WO2004005308A2 (en) 2002-07-08 2004-01-15 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
NZ537690A (en) 2002-07-15 2009-07-31 Univ Texas Antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections
EP1547607A4 (en) * 2002-08-02 2008-11-26 Dainippon Sumitomo Pharma Co PREPARATION OF A COMPONENT OF BACTERIA CELL WALL SKELETON
US20040265337A1 (en) * 2002-08-21 2004-12-30 Zsebo Krisztina M. Method of generating an immune response and compositions used for same
ES2422171T3 (es) * 2004-02-11 2013-09-09 Ligocyte Pharmaceuticals Inc Antígenos de carbunco y procedimientos de uso
EP1741438A4 (en) * 2004-04-22 2009-08-26 Dainippon Sumitomo Pharma Co PHARMACEUTICAL PREPARATION CONTAINING SKELETAL COMPONENT OF BACTERIAL CELL WALL
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US8128921B2 (en) * 2006-07-11 2012-03-06 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
WO2011034950A1 (en) 2009-09-16 2011-03-24 Vaxart, Inc. Immunization strategy to prevent h1n1 infection
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3632458A1 (en) 2013-07-26 2020-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
CN105555306B (zh) 2013-09-19 2019-12-03 诺瓦瓦克斯股份有限公司 免疫原性中东呼吸综合征冠状病毒(MERS-CoV)组合物和方法
CN106255508B (zh) 2014-02-20 2020-07-07 瓦克萨特公司 用于小肠递送的制剂
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
WO2016200951A1 (en) 2015-06-12 2016-12-15 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens
CN109069440A (zh) 2016-03-02 2018-12-21 得克萨斯州大学系统董事会 用于免疫治疗的激活sting的纳米疫苗
US11850279B2 (en) 2016-07-13 2023-12-26 Ohio State Innovation Foundation Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
US11376320B2 (en) 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2

Also Published As

Publication number Publication date
GB2122083A (en) 1984-01-11
DE3318567A1 (de) 1984-01-12
JPS6256135B2 (it) 1987-11-24
DE3318567C2 (de) 1987-01-29
FR2527443A1 (fr) 1983-12-02
US4436728A (en) 1984-03-13
JPS58222025A (ja) 1983-12-23
CA1217136A (en) 1987-01-27
IT8321288A0 (it) 1983-05-25
FR2527443B1 (fr) 1986-11-21
GB8313053D0 (en) 1983-06-15
GB2122083B (en) 1985-12-18

Similar Documents

Publication Publication Date Title
IT1164243B (it) Composizione farmaceutica contenente almeno in parte quantitativi terapeuticamente efficaci di endotossina detossificata raffinata ed il suo impiego terapeutico
IT1164244B (it) Composizione farmaceutica contenente almeno in parte endotossina detossificata e suo impiego terapeutico
SE8302774D0 (sv) Raffinerad, detoxifierad endotoxinprodukt samt sett att framstella detsamma jemte en terapeutisk komposition som innehaller produkten
ZA791797B (en) Use of antioestrogens and antigonadotropically active antiandrogens for the prophylaxis and therapy of prostate hyperplasia
NL7900871A (nl) Werkwijze voor de therapeutische behandeling van hyperlipidemie en hyperlipiproteinemie.
IT8027029A0 (it) Complessi platino-diamminici e formulazioni farmaceutiche per il trattamento del cancro che licontengono.
IT7928079A0 (it) Dispositivo per interventi chirurgici in cavita' del corpo umano.
ZA796708B (en) Therapeutic agents
IT7849929A0 (it) Procedimento e dispositivo per il trattamento terapeutico di emorroidi
ES512992A0 (es) "aparato para el tratamiento del cabello y del cuero cabelludo".
EG15007A (en) Device for the proplylact ic ore therapeutic treatment of cattle
GB2081094B (en) The use of dithiocarbamic compounds in cancer therapy
ES546701A0 (es) Procedimiento para preparar un agente terapeutico a base de celulas tumorales humanas y eventualmente, neuraminidasa.
ZA792390B (en) Therapeutic agents
GB2013181B (en) Therapeutic agents
GB2023416B (en) Therapeutic chair
GB2019836B (en) Therapeutic agents
ZA796759B (en) Dihydropyridazinones, their preparation and therapeutic agents containing these compounds
IT7824578A0 (it) Composizione farmaceutica per la terapia di stati di frigidita' ed impotenza.
EP0285906A3 (en) Active agent for combating tumours
DE3374066D1 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor
GB2011890B (en) Therapeutic agents
GB2011891B (en) Therapeutic agents
GB2013179B (en) Therapeutic agents
IT1130970B (it) Agente terapeutico per il trattamento del reumatismo